Jaen Juan C. sold $878K of RCUS (indirect holdings)
Jaen Juan C. (President) sold 31,431 indirectly-held shares of Arcus Biosciences, Inc. (RCUS) at an average of $27.92 ($27.03–$29.66, $0.88M total) across 4 trades over 2026-06-22 to 2026-06-24 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the officer’s open-market sale amount and timing (31,431 shares; ~$877.5K total) executed under a pre-arranged 10b5-1 plan.
Market read
Traders may monitor for follow-on insider activity, but this specific disclosure is unlikely to change valuation absent other catalysts.
What to watch
The filing does not disclose reasons for the sale, and the net impact depends on whether other insiders/funds are simultaneously buying or selling.
Background
The article is an SEC Form 4 insider transaction for Arcus Biosciences, Inc. (RCUS) filed on 2026-06-24.
Ticker impact
Arcus Biosciences insider Form 4 shows President Jaen Juan C. sold ~$877.5K of RCUS shares under a 10b5-1 plan (S trades, 6/22–6/24).
Low likelihood of a sustained price move; any reaction is likely short-lived and sentiment-driven.
The disclosure is a Form 4 open-market sale by an officer with an explicitly pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.
Market effects
Minimal; single-company insider transaction without new clinical/financial/regulatory information.
None indicated.
None indicated.
Counterpoint
Because the trades are under a 10b5-1 plan, the sale may reflect scheduled liquidity needs rather than bearish expectations.
Key entities
- issuerArcus Biosciences, Inc.
RCUS; subject of the Form 4 insider transaction disclosure.
- insiderJaen Juan C.
President; sold RCUS shares via open-market transactions under a 10b5-1 plan.